Scott Reed Lambert, MD
Ophthalmology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 3
Offices
3 locations · Lpch Medical Group Div of Lucile · Stanford Health Care
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lambert’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G53052 · Current
Licensed to practise in California · since 2008 · expires 2027-07-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$52,874
Medicare paid this office $52,874 for 135 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Realignment of horizontal eye muscle | 18 | $9,605 | $506 |
| Realignment of vertical eye muscle | 20 | $7,768 | $370 |
| Realignment of eye by repair of 2 horizontal muscles | 12 | $7,621 | $635 |
| Placement of adjustable sutures during eye muscle surgery | 26 | $4,890 | $181 |
| New patient visit (45+ min) | 41 | $4,771 | $116 |
See all 10 services
| Realignment of horizontal eye muscle | 18 | $9,605 | $506 |
| Realignment of vertical eye muscle | 20 | $7,768 | $370 |
| Realignment of eye by repair of 2 horizontal muscles | 12 | $7,621 | $635 |
| Placement of adjustable sutures during eye muscle surgery | 26 | $4,890 | $181 |
| New patient visit (45+ min) | 41 | $4,771 | $116 |
| Exam to measure eye deviation and range of motion | 119 | $4,243 | $31 |
| Return visit (30+ min) | 42 | $3,536 | $82 |
| Realignment of eye muscle following injury or eye surgery | 18 | $3,241 | $180 |
| Realignment of eye muscle complicated by scarring or restrictive muscle movement | 11 | $2,244 | $204 |
| New patient visit (30+ min) | 13 | $806 | $62 |
Who their Medicare patients are
135 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 10% · Women 64% · Also on Medicaid 19% · Health risk score 1.01. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 60% · Diabetes 22% · Coronary heart disease 19% · Depression 19% · Cancer 17% · Atrial fibrillation 17% · Chronic kidney disease 12% · Stroke 10% · COPD 8%.
The office billed $479,412, Medicare allowed $68,530 and paid $52,874; for 380 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 135 | 380 | 74 | 1.01 | $479,412 | $52,874 |
| 2023 | 92 | 256 | 73 | 1.16 | $318,413 | $35,843 |
| 2022 | 71 | 189 | 72 | 0.98 | $256,997 | $31,487 |
| 2021 | 70 | 171 | 70 | 1.19 | $189,925 | $28,978 |
| 2020 | 50 | 121 | 72 | 1.04 | $160,904 | $20,814 |
| 2019 | 52 | 117 | 71 | 1.03 | $77,185 | $12,137 |
| 2018 | 47 | 104 | 71 | 0.97 | $85,101 | $11,646 |
| 2017 | 39 | 122 | 71 | 1.02 | $157,666 | $19,912 |
| 2016 | 65 | 126 | 67 | 1.00 | $110,998 | $14,486 |
| 2015 | 71 | 141 | 65 | 1.26 | $97,019 | $14,543 |
| 2014 | 78 | 162 | 66 | 1.16 | $143,556 | $20,987 |
| 2013 | 71 | 159 | 66 | 1.16 | $139,129 | $20,200 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Realignment of horizontal eye muscle | 15 | $9,470 | $498 |
| Realignment of eye muscle complicated by scarring or restrictive muscle movement | 13 | $3,385 | $226 |
| Placement of adjustable sutures during eye muscle surgery | 14 | $3,091 | $182 |
| Return visit (30+ min) | 34 | $3,010 | $81 |
| Exam to measure eye deviation and range of motion | 78 | $2,818 | $32 |
| Long return visit (40+ min) | 13 | $1,596 | $123 |
| New patient visit (45+ min) | 13 | $1,384 | $106 |
| New patient visit (30+ min) | 19 | $1,288 | $68 |
2022: 5 services
| Placement of adjustable sutures during eye muscle surgery | 19 | $3,693 | $194 |
| Return visit (30+ min) | 24 | $1,979 | $76 |
| Exam to measure eye deviation and range of motion | 53 | $1,743 | $31 |
| New patient visit (45+ min) | 14 | $1,605 | $115 |
| New patient visit (30+ min) | 14 | $911 | $65 |
2021: 5 services
| Realignment of vertical eye muscle | 11 | $5,633 | $512 |
| New patient visit (45+ min) | 20 | $2,564 | $128 |
| Exam to measure eye deviation and range of motion | 47 | $1,627 | $31 |
| Return visit (30+ min) | 15 | $1,262 | $84 |
| New patient visit (30+ min) | 11 | $838 | $76 |
2020: 4 services
| Realignment of vertical eye muscle | 11 | $7,615 | $692 |
| Exam to measure eye deviation and range of motion | 30 | $920 | $31 |
| New patient visit (30+ min) | 15 | $906 | $60 |
| Established patient problem focused exam of visual system | 15 | $845 | $50 |
2019: 3 services
| Exam to measure eye deviation and range of motion | 41 | $1,443 | $33 |
| Established patient problem focused exam of visual system | 23 | $1,049 | $42 |
| New patient visit (30+ min) | 15 | $995 | $66 |
2018: 2 services
| Established patient problem focused exam of visual system | 25 | $1,098 | $44 |
| Exam to measure eye deviation and range of motion | 32 | $1,086 | $33 |
2017: 4 services
| Placement of adjustable sutures during eye muscle surgery | 12 | $1,855 | $155 |
| Exam to measure eye deviation and range of motion | 31 | $1,225 | $34 |
| Established patient problem focused exam of visual system | 16 | $884 | $49 |
| New patient visit (30+ min) | 12 | $747 | $62 |
2016: 2 services
| Exam to measure eye deviation and range of motion | 41 | $1,894 | $43 |
| New patient visit (15+ min) | 15 | $363 | $24 |
2015: 2 services
| Exam to measure eye deviation and range of motion | 57 | $3,216 | $48 |
| New patient visit (15+ min) | 22 | $1,077 | $49 |
2014: 2 services
| Exam to measure eye deviation and range of motion | 52 | $2,820 | $48 |
| New patient visit (15+ min) | 15 | $821 | $55 |
2013: 3 services
| Exam to measure eye deviation and range of motion | 50 | $2,477 | $46 |
| Established patient problem focused exam of visual system | 29 | $1,713 | $57 |
| New patient problem focused exam of visual system | 15 | $792 | $53 |
Medicaid work
$32,561 in 2024
Medicaid paid $32,561 for 469 billed services this clinician did in 2024, up to 42 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 190 | $23,016 |
| SENSORIMOTOR EXAMINATION | 83 | $4,318 |
| DETERMINATION REFRACTIVE STATE | 165 | $2,540 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 16 | $1,652 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 15 | $1,034 |
| 2024 | 469 | 5 | 42 | $32,561 |
| 2023 | 642 | 6 | 32 | $39,637 |
| 2022 | 361 | 4 | 29 | $26,561 |
| 2021 | 295 | 4 | 23 | $24,076 |
| 2020 | 89 | 3 | 19 | $6,191 |
| 2019 | 120 | 4 | 18 | $8,870 |
| 2018 | 162 | 4 | 18 | $10,917 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 243 | $22,577 |
| SENSORIMOTOR EXAMINATION | 220 | $11,202 |
| DETERMINATION REFRACTIVE STATE | 125 | $1,997 |
| New patient visit (45+ min) | 15 | $1,510 |
| Short return visit (20+ min) | 27 | $1,211 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 12 | $1,140 |
2022
| Return visit (30+ min) | 215 | $19,331 |
| SENSORIMOTOR EXAMINATION | 64 | $3,384 |
| New patient visit (45+ min) | 24 | $2,848 |
| DETERMINATION REFRACTIVE STATE | 58 | $999 |
2021
| Return visit (30+ min) | 193 | $17,026 |
| SENSORIMOTOR EXAMINATION | 70 | $4,104 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 14 | $1,601 |
| Short return visit (20+ min) | 18 | $1,345 |
2020
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 65 | $4,309 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 12 | $1,130 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 12 | $751 |
2019
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 50 | $3,506 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 26 | $2,669 |
| OFF/OP CONSLTJ NEW/EST SF 20 | 17 | $1,392 |
| SENSORIMOTOR EXAMINATION | 27 | $1,303 |
2018
| OFF/OP CONSLTJ NEW/EST SF 20 | 59 | $4,485 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 42 | $2,689 |
| SENSORIMOTOR EXAMINATION | 46 | $2,188 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 15 | $1,555 |
Money from drug and device companies
$3,273 in 2025
| 2025 | 2 | 10 | $3,250 | $3,273 |
| 2024 | 1 | 4 | $1,813 | $1,813 |
| 2023 | 3 | 10 | $3,958 | $4,330 |
| 2022 | 2 | 7 | $3,075 | $3,212 |
| 2021 | 1 | 4 | $1,668 | $1,668 |
| 2020 | 1 | 2 | $938 | $938 |
| 2019 | 2 | 11 | $4,650 | $4,752 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Vertex Pharmaceuticals | None | $3,250 | 9 payments
|
| Glaukos | Istent Infinite | $23 | 1 payment
|
See all 10 published payments
| Glaukos | Meals · 2025-12-17 | Istent Infinite | $23 |
| Vertex Pharmaceuticals | Consulting · 2025-12-03 | None | $500 |
| Vertex Pharmaceuticals | Consulting · 2025-09-24 | None | $250 |
| Vertex Pharmaceuticals | Consulting · 2025-09-24 | None | $250 |
| Vertex Pharmaceuticals | Consulting · 2025-08-26 | None | $250 |
| Vertex Pharmaceuticals | Consulting · 2025-08-26 | None | $250 |
| Vertex Pharmaceuticals | Consulting · 2025-07-23 | None | $375 |
| Vertex Pharmaceuticals | Consulting · 2025-05-22 | None | $438 |
| Vertex Pharmaceuticals | Consulting · 2025-01-15 | None | $563 |
| Vertex Pharmaceuticals | Consulting · 2025-01-15 | None | $375 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,813
| Vertex Pharmaceuticals | None | $1,813 | 4 payments
|
2023: $4,330
| Vertex Pharmaceuticals | None | $3,958 | 8 payments
|
| Lumenis BE | Optilight | $252 | 1 payment
|
| Genentech USA | Vabysmo | $121 | 1 payment
|
2022: $3,212
| Vertex Pharmaceuticals | None | $3,075 | 6 payments
|
| Genentech USA | Vabysmo | $137 | 1 payment
|
2021: $1,668
| Vertex Pharmaceuticals | None | $1,668 | 4 payments
|
2020: $938
| Vertex Pharmaceuticals | None | $938 | 2 payments
|
2019: $4,752
| Vertex Pharmaceuticals | None | $4,650 | 10 payments
|
| Novartis Pharmaceuticals | None | $102 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| EyePoint Pharmaceuticals US, Inc. · Evaluate the Safety of Dexycu for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract · 2023 | Their institution | $50,109 |
| EyePoint Pharmaceuticals US, Inc. · Evaluate the Safety of Dexycu for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (Eyp-Dip-001) · 2022 | Their institution | $24,102 |
| Travere Therapeutics, Inc. · Protocol No: 018ctxx15001 · 2020 | Their institution | $17,781 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study To Evaluate the Safety of Dexycu for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract · 2024 | Their institution | $10,963 |
| Travere Therapeutics, Inc. · Ctx Prevalence: Ctx Observational Study in Patients With Early Onset Bilateral Cateracts · 2021 | Their institution | $7,917 |
| Retrophin, Inc. · 018ctxx15001 · 2019 | Their institution | $546 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1093748766
- Licence
- CA G53052, GA 030809California G53052: Current · expires 2027-07-31
- Trained
- Yale University School of Medicine, 1983
- Group
- Lpch Medical Group Div of Lucile · Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207WX0110X (207WX0110X); Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1804 Embarcadero Rd, Suite 100, Palo Alto, CA, 94303
- NPI first listed
- 2006-07-08
- NPI last updated
- 2024-04-04
- NPI record certified
- 2024-04-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305